Mycoses

Human

Environmental
Industrial

The Fungi

Video Bank

Drugs

Environmental
Industrial

Agricultural

Laboratory

Histopathology

  Education &
  Tools

Links

CME

Conference
Highlights

Events Calendar

About Us

Editorial Board

Editorial Staff

Kudos

The Fungi

Video Bank

This page updated:
1/27/2007 9:23:00 AM

DoctorFungus - All Rights Reserved © 2007 Copyright
& Privacy Policy

Site built and designed for doctorfungus by Webillustrated

You are here: Mycoses >

Navigate this section from here:

Sporotrichosis

None

Sporotrichosis refers to the infection caused by the dimorphic fungus Sporothrix schenckii. The disease has been described worldwide, however it is more common in tropical and subtropical America [1898, 2251]. Sporotrichosis is acquired through direct inoculation into the skin and rarely via inhalation of conidia. As a consequence, the majority of cases are localized lesions affecting the skin and subcutaneous tissues with minimal if any systemic manifestation. Skin lesions characteristically follow lymphatic pathways, but the lymph nodes themselves are not usually involved. The initial erythematous papulonodular lesions evolve into either smooth or verrucose painless nodules of about 3 cm that may ulcerate and drain [1909]. There is also a clinical variety called "the fixed form" [241, 1273]. The most common form of extracutaneous sporotrichosis is osteoarthritis. Pulmonary sporotrichosis has also been described. Disseminated forms of disease are seen on occasion, and these classically affect immunosuppressed individuals [1396, 2440]. With the advent of the HIV epidemic the frequency of this presentation has increased [39, 282, 606].

CATEGORIES	NOTES
Cutaneous	Varieties: Lymphocutaneous sporotrichosis: affects the skin, subcutaneous tissues and regional lymphatics Fixed sporotrichosis: skin lesion evolves locally without spread
Osteoarticular	Arthritis and tenosynovitis that may affect joints of the hands, elbows, ankles or knees. The spine, hips and shoulders are usually not involved. Sinus tracts and local spread to adjacent bones may develop.
Pulmonary	Classically produce enlarging cavitary lesions, unilateral or bilateral usually with pulmonary infiltrates. May produce pleural effusion and hilar lymphadenopathy Associated with alcoholism, diabetes, corticosteroid use, sarcoidosis and tuberculosis
Meningitis	Rare Produce a typical chronic meningitis picture. CSF cultures have a low sensitivity, serologic testing may be necessary
Disseminated	Varieties: Multifocal tenosynovitis and arthritis that mimic gonococcal infection or seronegative spondyloarthropathy Widespread visceral involvement associated with fungemia. Many organs may be involved, including the central nervous system (meninges or parenchyma), liver, spleen, bone marrow, and colon

Special resource: You may also want to refer to the Infectious Disease Society of America-Mycoses Study Group (IDSA-MSG) Practice Guidelines for this disease. It is available at the IDSA website.

Sporotrichosis is in general an indolent infection that requires prolonged therapy but usually responds [1168]. Due to the temperature sensitivity of the fungus, local application of hyperthermia can be used for the treatment of cutaneous lesions. However, systemic therapy, especially with oral azoles such as itraconazole, has shown to be very effective [1898, 2086]. Therapy with iodide (given as a saturated solution of potassium iodide, or SSKI) is also effective [1168]. Treatment is continued for 3 to 6 months in cases of skin lesions and at least 12 months for osteoarticular forms [1168]. Prognosis of disseminated disease is grave. Amphotericin B is reserved to treat relapsed lymphocutaneous disease, pulmonary, disseminated sporotrichosis as well as for serious infections presenting during pregnancy [1168]. Antibacterial antibiotics are useful when secondary bacterial infections occur.

The pattern of inflammation is characteristically well circumscribed and granulomatous with central areas of acute suppuration. In the skin, this pattern is similar to that seen in blastomycosis and coccidioidomycosis. Demonstration of the organism in tissue may be difficult because the fungi are not numerous. It may be necessary to search through many serial sections before observing the organism. The fungus is yeast-like, subglobose to ovoid, and 3-5 µm in diameter. The organisms are often described as cigar-shaped. The yeasts are not encapsulated. An asteroid body may be present and consists of globose to ovoid, basophilic cells, 3-5 µm in diameter with radiating eosinophilic rays up to 10 µm in diameter. An asteroid body formation appears to be more common in secondary lesions than in primary ones.

Direct examination

Typically unrewarding. Fluorescent antibody staining techniques may be helpful. Diastase digestion prior to staining with H & E or PAS may be helpful.

Isolation

Inoculate the aspirates, material from Culturettes, or swabbings from open lesions onto Sabouraud dextrose agar and/or Inhibitory Mould Agar and/or BHI with Gentamycin and Chloramphenicol with 10% sheep blood, and a medium containing cycloheximide. Incubate the media at 30°C. Growth is usually present in 3-5 days.

Laboratory confirmation

The mould-to-yeast form conversion is necessary since other fungi are morphologically similar. Transfer the fungus to brain heart infusion agar and incubate at 37°C in 5-10 % CO2

Plant material

Standardized testing procedures are not available. Microbiological resistance has not been demonstrated.

Yeast phase of Sporothrhix schenckii

lymphocutaneous lesions spreading up the arm

Typical colony of Sporothrix schenckii in its mould phase

References

39. Al-Tawfiq, J. A., and K. K. Wools. 1998. Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection. Clin Infect Dis. 26:1403-1406.

241. Bickley, L. K., I. J. Berman, and A. F. Hoodd. 1985. Fixed cutaneous sporotrichosis: Unusual histopathology following intralesional corticosteroid administration. J. Amer. Acad. Dermatol. 12:1007-1012.

282. Bolao, F., D. Podzamczer, M. Ventin, and F. Gudiol. 1994. Efficacy of acute phase and maintenance therapy with itraconazole in an AIDS patient with sporotrichosis. Eur. J. Clin. Microbiol. Infect. Dis. 13:609-12.

606. Donabedian, H., E. O'Donnell, C. Olszewski, R. D. MacArthur, and N. Budd. 1994. Disseminated cutaneous and meningeal sporotrichosis in an AIDS patient. Diagn. Microbiol. Infect. Dis. 18:111-115.

1168. Kauffman, C. A., R. Hajjeh, S. W. Chapman, and Mycoses Study Group. 2000. Practice guidelines for the management of patients with sporotrichosis. Clin. Infect. Dis. 30:684-687.

1273. Kwon-Chung, K. J. 1979. Comparison of isolates of Sporothrix schenckii obtained from fixed cutaneous lesions with isolates from other types of lesions. J. Infect. Dis. 139:424-431.

1396. Lynch, P. J., J. J. Voorhees, and E. R. Harrell. 1970. Systemic sporotrichosis. Ann. Intern. Med. 73:23-30.

1898. Restrepo, A., J. Robledo, I. Gomez, A. M. Tabares, and R. Gutierrez. 1986. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch. Dermatol. 122:413-417.

1909. Rex, J. H., and P. C. Okhuysen. 2000. Sporothrix schenckii, p. 2695-2698. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 5th ed. Churchill Livingstone, New York.

2086. Sharkey-Mathis, P. K., C. A. Kauffman, J. R. Graybill, D. A. Stevens, J. S. Hostetler, G. Cloud, W. E. Dismukes, and Other Members of the NIAID Mycoses Study Group. 1993. Treatment of sporotrichosis with itraconazole. Am. J. Med. 95:279-285.

2251. Travassos, L. R., and K. O. Lloyd. 1980. Sporothrix schenckii and related species of Ceratocystis. Microbiol. Rev. 44:683-721.

2440. Wilson, D. E., J. J. Mann, J. E. Bennett, and J. P. Utz. 1967. Clinical features of extracutaneous sporotrichosis. Medicine. 46:265-279.

Home | Image Bank | Lecture Bank | Knowledgebase | Site Map | Contact Us |
The Fungi | Mycoses | Drugs |
Laboratory | Education & Tools | About Us

bttm_banner_indv2_02[1].gif